Dabur India's foreign subsidiaries are under the scanner for manufacturing cancer-causing products in the United States and Canada, where complainants are allegedly suffering from ovarian cancer, uterine cancer, and other related health issues due to hair-relaxer products. Over 5,400 cases have been registered against Dabur in both state and federal courts.
While the complainants have made a legal move, Dabur on the contrary refused the allegations saying, "These allegations are based on unsubstantiated and incomplete study".
There are 27 subsidiary companies of Dabur India globally, while the ones who are facing multiple lawsuits are Namaste Laboratories LLC, Dermoviva Skin Essentials Inc, and Dabur International Ltd. – according to a late-night regulatory filing from the homegrown FMCG and Ayurvedic products maker on Wednesday.
Dabur generated a revenue of Rs 2,867 crore, which was 11.1% in constant currency terms in FY23. According to its latest report, Dabur has eight international manufacturing locations.
